A retirement community desk clerk’s perspective on dementia
By
Kimberly Hollifield
Jul 05, 2022
As a desk clerk in a retirement community, I observed many residents living with dementia. This experience made a big impression on me.
Research focuses on diagnosing, lessening effects of Alzheimer’s disease
By
Kimberly Bonvissuto
Jun 28, 2022
More than 6 million Americans are living with Alzheimer’s disease, costing the nation $321 billion in 2022, according to the Alzheimer’s Association. A variety of studies and pilot programs are underway...
New Alzheimer’s disease drug delivers disappointing results
Jun 17, 2022
The trial was the first to test a drug meant to delay or halt mental decline in people who have a genetic predisposition.
Retinal layer thickness linked to cognitive decline in older adults
May 27, 2022
Thinner baseline total macular retinal nerve fiber layer thickness was associated with a larger decline in cognitive function test scores during follow-up.
One in three Alzheimer’s, dementia cases tied to modifiable risk factors
May 11, 2022
Risk factors differ based on sex and race and ethnicity.
Interventions for Alzheimer’s disease improve cognition in men, women
May 03, 2022
Individualized multidomain interventions are equally effective for improving cognition in women and men.
Healthy lifestyle tied to longer life, delayed onset of dementia
Apr 14, 2022
Healthy lifestyle in seniors is linked to longer life expectancy and a larger proportion of remaining years spent without Alzheimer’s dementia.
Medicare will only cover Aduhelm for patients in clinical trials
Apr 08, 2022
The decision is meant to protect patients while gathering more clinical data on whether the medication actually helps slow declines in thinking.
Neuroimaging measures linked to stages of memory impairment
Mar 04, 2022
The presence of Alzheimer’s disease pathology is related to Stages of Objective Memory Impairment in cognitively unimpaired older adults.
AAN issues review of evidence for aducanumab in Alzheimer’s disease
Mar 03, 2022
A class I study shows that single doses of aducanumab are safe and well-tolerated; class II studies show reduced amyloid deposition on brain PET at one year.